Article
A randomized controlled trial of pretransplant antiviral therapy to prevent recurrence of hepatitis C after liver transplantation.
Hepatology (Baltimore, Md.) - 1 May 2013
Everson Gregory T, Terrault Norah A, Lok Anna S, Rodrigo Del R, Brown Robert S, Saab Sammy, Shiffman Mitchell L, Al-Osaimi Abdullah M S, Kulik Laura M, Gillespie Brenda W, Everhart James E
Abstract excerpt
UNLABELLED: Hepatitis C virus (HCV) infection recurs in liver recipients who are viremic at transplantation. We conducted a randomized, controlled trial to test the efficacy and safety of pretransplant pegylated interferon alpha-2b plus ribavirin (Peg-IFN-α2b/RBV) for prevention of post-transplant HCV recurrence. Enrollees had HCV and were listed for liver transplantation, with either potential living donors or...
Topics
- Antiviral Agents
- Dose-Response Relationship, Drug
- Drug Therapy, Combination
- End Stage Liver Disease
- Female
- Genotype
- Hepacivirus
- Hepatitis C, Chronic
- Humans
- Interferon alpha-2